Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the American Society of Nephrology

• Publication date

  1999-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 10405199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin.

  1998cited by this paper
• Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients.

  1998cited by this paper
• Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin.

  1998cited by this paper
• Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade.

  1998cited by this paper
• Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass.

  1998cited by this paper
• Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels.

  1997cited by this paper
• Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension.

  1997cited by this paper
• Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells.

  1997cited by this paper
• Uremia enhances the blood pressure response to erythropoietin.

  1997cited by this paper
• Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats.

  1997cited by this paper
• Effect of chronic ETA-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats.

  1997cited by this paper
• Regulation of brain capillary endothelial cells by P2Y receptors coupled to Ca2+, phospholipase C and mitogen‐activated protein kinase

  1997cited by this paper
• Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass.

  1997cited by this paper
• Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist.

  1997cited by this paper
• Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.

  1996cited by this paper
• Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.

  1996cited by this paper
• The role of ETB receptors in normotensive and hypertensive rats as revealed by the non‐peptide selective ETB receptor antagonist Ro 46‐8443

  1996influential reference
• Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats.

  1996cited by this paper
• Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids.

  1996cited by this paper
• Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure.

  1996cited by this paper
• Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients.

  1995cited by this paper
• In vivo and in vitro pressor effects of erythropoietin in rats.

  1995cited by this paper
• The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system.

  1995cited by this paper
• Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy.

  1994cited by this paper
• Erythropoietin receptor mRNA expression in human endothelial cells.

  1994cited by this paper
• Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

  1994cited by this paper
• Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy.

  1994cited by this paper
• Clearance of circulating endothelin-1 by ETB receptors in rats.

  1994cited by this paper
• Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells.

  1993cited by this paper
• Effect of different endothelin receptor antagonists and of the novel non‐peptide antagonist Ro 46‐2005 on endothelin levels in rat plasma

  1993cited by this paper
• Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression.

  1993cited by this paper
• A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression.

  1993cited by this paper
• Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia.

  1993cited by this paper
• Erythropoietin increases blood pressure in normotensive and hypertensive rats.

  1993cited by this paper
• Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.

  1993cited by this paper
• Polar secretion of endothelin-1 by cultured endothelial cells.

  1992cited by this paper
• Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems.

  1991cited by this paper
• Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men

  1991cited by this paper
• Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.

  1991cited by this paper
• Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels.

  1991cited by this paper
• Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis.

  1990cited by this paper
• Hypertension following erythropoietin therapy in anemic hemodialysis patients.

  1990cited by this paper
• Erythropoietin treatment of anemia associated with multiple myeloma.

  1990cited by this paper
• Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.

  1990cited by this paper
• Recombinant human erythropoietin for patients with AIDS treated with zidovudine.

  1990cited by this paper
• Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

  1988cited by this paper

• Long-acting erythropoiesis-stimulating agent (ESA) induces physiological erythropoiesis via improvement of iron availability

  2021cites this paper
• Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis

  2018cites this paper
• Mechanisms and mediators of hypertension induced by erythropoietin and related molecules

  2018cites this paper
• Resistant Hypertension in Chronic Kidney Disease

  2017cites this paper
• Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease

  2017cites this paper
• New Strategies for Anaemia Management in Chronic Kidney Disease.

  2017cites this paper
• Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease

  2017cites this paper
• Treatment of Hypertension in Light of the New Guidelines: Pharmacologic Approaches Using Combination Therapies

  2017cites this paper
• An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease

  2016cites this paper
• Ischemic Tolerance in Uremic Rabbits

  2015cites this paper
• Endothelin antagonists in hypertension and kidney disease

  2013influential citation
• Effects of Recombinant Human Erythropoietin on Resistance Artery Endothelial Function in Stage 4 Chronic Kidney Disease

  2013cites this paper
• Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

  2013cites this paper
• Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice.

  2011cites this paper
• Antihypertensive Agents in Hemodialysis Patients: A Current Perspective

  2010influential citation
• Role of oxidative stress in erythropoietin-induced hypertension in uremic rats.

  2010cites this paper
• Expression von Genen des Endothelin-, Renin-Angiotensin- und Stickstoffmonoxidsystems in Mäusen mit Endothelin-Typ B-Rezeptor-Defizit

  2010cites this paper
• Hypertension in dialysis and kidney transplant patients.

  2009cites this paper
• EFFECTS OF ERYTHROPOIETIN AND GROWTH HORMONE ON HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS IN 5/6 NEPHRECTOMIZED MALE ALBINO RATS

  2009cites this paper
• Anemia in Chronic Kidney Disease Patients

  2008cites this paper
• Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system.

  2008cites this paper
• Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?

  2008cites this paper
• Renin-Angiotensin-Aldosterone System Antihypertensive and Renal Protective Effects of Renin-Angiotensin System Blockade in Uremic Rats Treated With Erythropoietin

  2006cites this paper
• Effect of endothelin-1 on erythropoietin production in a rat model under normoxia and functional carbon monoxide-induced hypoxia

  2006cites this paper
• HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Nonhematologic Complications of Erythropoietin Therapy

  2006cites this paper
• The future of endothelin-receptor antagonism as treatment for systemic hypertension

  2006cites this paper
• Érythropoïèse et bronchopneumopathie chronique obstructive

  2006cites this paper
• Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.

  2006cites this paper
• Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats.

  2005cites this paper
• Beneficial and ominous aspects of the pleiotropic action of erythropoietin

  2004cites this paper
• SURVEY REVIEW / SYNTHÈSE D'ENSEMBLE

  2003cites this paper
• Endothelin-1 in chronic renal failure and hypertension.

  2003cites this paper
• Erythropoietin Administration In Vivo Increases Vascular Nitric Oxide Synthase Expression

  2003cites this paper
• Einfluß von Endothelin-Rezeptor-Antagonisten, Losartan und Nebivolol auf die Isoformen der myokardialen Protein Kinase C in der Urämie

  2003cites this paper
• Erythropoietin: Physiology and Pharmacology Update 2

  2003cites this paper
• Relationship between Eicosanoids and Endothelin-1 in the Pathogenesis of Erythropoietin-induced Hypertension in Uremic Rats

  2003cites this paper
• Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa

  2002cites this paper
• Endothelin A but Not Endothelin B Receptor Blockade Reduces Capillary Permeability in Severe Experimental Pancreatitis

  2002cites this paper
• Improving Prognosis for Kidney Disorders

  2002cites this paper
• New therapeutics that antagonize endothelin: promises and frustrations

  2002cites this paper
• Function of the endothelinB receptor in cardiovascular physiology and pathophysiology

  2002cites this paper
• Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology.

  2002cites this paper
• Erythropoietin and anemia.

  2001cites this paper
• Treatment with a combined endothelin A/B-receptor antagonist does not prevent chronic renal allograft rejection in rats.

  2000cites this paper
• CHRONIC NITRIC OXIDE INHIBITION AGGRAVATES HYPERTENSION IN ERYTHROPOIETIN-TREATED RENAL FAILURE RATS

  2000cites this paper
• Vascular effects of erythropoietin and anemia correction.

  2000cites this paper
• Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats.

  1999cites this paper
• Pharmacology of the EndothelinA Receptor Antagonist: LU 135252

  1998cites this paper